Evidence map›Paper›PMID 27588344›Full record

ReviewVirulence2017

Antifungal stewardship considerations for adults and pediatrics.

Rana F Hamdy, Theoklis E Zaoutis, Susan K Seo

Abstract readReview
In one paragraph

Review in Virulence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Antifungal Stewardship in Invasive Fungal Infections, a Systematic Review.Advances in experimental medicine and biology · 2025
    Pooled it
  2. Guideline
  3. Brazilian guidelines for the diagnosis and treatment of candidemia and invasive candidiasis in adults and children.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Guideline
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Stewardship: it's going viral.Infection prevention in practice · 2024
    Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rana F Hamdya Division of Infectious Diseases , Children's National Health System , Washington , DC , USA.
Theoklis E Zaoutisb Division of Infectious Diseases, Department of Pediatrics , The Children's Hospital of Philadelphia , Philadelphia , PA , USA.
Susan K Seoc Department of Medicine , Infectious Disease Service, Memorial Sloan Kettering Cancer Center , New York , NY , USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Clinical Pharmacoepidemiology Training ProgramT32GM075766 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI Sean Hennessy, Charles Edward Leonard · 2006 to 2026
$8.4M
NCI NIH HHS P30 CA008748NIAID NIH HHS L40 AI126536NIGMS NIH HHS T32 GM075766
6 · The paper itself

Abstract

Antifungal stewardship refers to coordinated interventions to monitor and direct the appropriate use of antifungal agents in order to achieve the best clinical outcomes and minimize selective pressure and adverse events. Antifungal utilization has steadily risen over time in concert with the increase in number of immunocompromised adults and children at risk for invasive fungal infections (IFI). Challenges in diagnosing IFI often lead to delays in treatment and poorer outcomes. There are also emerging data linking prior antifungal exposure and suboptimal dosing to the emergence of antifungal resistance, particularly for Candida. Antimicrobial stewardship programs can take a multi-pronged bundle approach to ensure suitable prescribing of antifungals via post-prescription review and feedback and/or prior authorization. Institutional guidelines can also be developed to guide diagnostic testing in at-risk populations; appropriate choice, dose, and duration of antifungal agent; therapeutic drug monitoring; and opportunities for de-escalation and intravenous-to-oral conversion.

Indexed as

Antimicrobial StewardshipDrug Resistance, FungalAdultAntifungal AgentsCandidaCandidiasisChildDrug MonitoringHumansImmunocompromised HostInvasive Fungal InfectionsMicrobial Sensitivity TestsPediatricsAntifungal Agentsantifungal resistanceantifungal stewardshipantimicrobial stewardship programhematologic malignancyinvasive aspergillosisinvasive candidiasisinvasive fungal infectionpediatricsrapid diagnosticstransplantation

Identifiers

PMID27588344
PMCPMC5626349

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.